Anke Maes
Impact in
- Hematology top 10%
- Multiple Myeloma Research and Treatments
Papers in
-
- Protein Degradation and Inhibitors 6
- Ubiquitin and proteasome pathways 4
- Histone Deacetylase Inhibitors Research 4
- Epigenetics and DNA Methylation 3
- Cancer-related gene regulation 2
- Hematology 12
- Multiple Myeloma Research and Treatments 11
- Co-authors
- Elke De Bruyne (20 shared papers)Karin Vanderkerken (18 shared papers)Kim De Veirman (18 shared papers)Eline Menu (18 shared papers)Ken Maes (11 shared papers)Philip Vlummens (10 shared papers)Jérôme Moreaux (8 shared papers)Dirk Hose (7 shared papers)
In The Last Decade
Anke Maes
21 papers receiving 415 citations
Peers
Comparison fields: 5 of 55
- Hematology 108
- Cancer Research 65
- Molecular Biology 262
- Immunology 75
- Oncology 89
Countries citing papers authored by Anke Maes
This map shows the geographic impact of Anke Maes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anke Maes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anke Maes more than expected).
Fields of papers citing papers by Anke Maes
This network shows the impact of papers produced by Anke Maes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anke Maes. The network helps show where Anke Maes may publish in the future.
Co-authors
The 25 scholars most cited alongside Anke Maes, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 21 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2018 | 49 | |
| 2 | 2017 | 43 | |
| 3 | 2015 | 41 | |
| 4 | 2019 | 34 | |
| 5 | 2022 | 33 | |
| 6 | 2017 | 30 | |
| 7 | 2022 | 27 | |
| 8 | 2022 | 24 | |
| 9 | 2020 | 20 | |
| 10 | 2022 | 15 | |
| 11 | 2023 | 14 | |
| 12 | 2022 | 14 | |
| 13 | 2023 | 14 | |
| 14 | 2022 | 13 | |
| 15 | 2019 | 13 | |
| 16 | 2022 | 12 | |
| 17 | 2019 | 12 | |
| 18 | 2022 | 5 | |
| 19 | 2016 | 2 | |
| 20 | 2014 | 1 |
About Anke Maes
Anke Maes is a scholar working on Molecular Biology, Hematology, Oncology, Cell Biology and Immunology, having authored 21 papers that have together received 417 indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (11 papers), Protein Degradation and Inhibitors (6 papers), Ubiquitin and proteasome pathways (4 papers), Histone Deacetylase Inhibitors Research (4 papers), Microtubule and mitosis dynamics (4 papers), Epigenetics and DNA Methylation (3 papers), Chemokine receptors and signaling (2 papers) and Cancer-related gene regulation (2 papers). The work is most often cited by research in Hematology (108 citations), Cancer Research (65 citations), Molecular Biology (262 citations), Immunology (75 citations) and Oncology (89 citations). Anke Maes has collaborated with scholars based in Belgium, France and Germany. Frequent co-authors include Elke De Bruyne, Karin Vanderkerken, Kim De Veirman, Eline Menu, Ken Maes, Philip Vlummens, Jérôme Moreaux, Dirk Hose, Alboukadel Kassambara and Nathan De Beule. Their work appears in journals such as Blood, Oncotarget, The Journal of Pathology, Cancer Letters and Journal for ImmunoTherapy of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.